OAS1 and cancer: The latest research indicates that the upregulation of OAS1 expression amplifies IFN signaling and sustains a high level of ISGs expression in cancer cells resistant to immune checkpoint blockade (ICB) therapy via the IFN-Inflammatory memory domains (IMDs), consequently augmenting their resistance to immunotherapy (77).